Long-term follow-up of transplanted mice showed that all recipients of Skp2+/+ ICN cells were terminal by week 12, whereas T-ALL development was significantly delayed in recipients of Skp2−/− ICN cells, with 50% survival at week 12 (Fig. 4c left panel). This evidence concerns the gene SKP2 and acute lymphoblastic leukemia.